**Temporal changes in cardiac troponin I are associated with risk of cardiovascular events in the general population:   
The Nord-Trøndelag Health Study**

Running head: Change in troponin I and cardiovascular risk

Magnus N Lyngbakken1, Helge Røsjø1, Oddgeir L Holmen2, Håvard Dalen3, Kristian Hveem2, Torbjørn Omland1

1 Division of Medicine, Akershus University Hospital, Lørenskog, Norway and Center for Heart Failure Research, University of Oslo, Oslo, Norway  
2 HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, Norway  
3 K.G. Jebsen Center for Exercise in Medicine, Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway

**Address for correspondence:**

Torbjørn Omland MD, PhD, MPH

Professor of Medicine, University of Oslo

Division of Medicine, Akershus University Hospital, Postboks 1000, 1478 Lørenskog, Norway

Tel: +47 40 10 70 50, Fax: +47 67 96 88 60, Email: [torbjorn.omland@medisin.uio.no](mailto:torbjorn.omland@medisin.uio.no)

**Keywords:** Biomarkers; Cardiovascular Disease; Epidemiology; Risk Prediction; Prognosis; Troponin.

**Abbreviations:** hs-cTn, cardiac troponin measured with a high-sensitivity assay; MI, myocardial infarction; HF, heart failure; hs-cTnT, cardiac troponin T measured with a high-sensitivity assay; hs-cTnI, cardiac troponin I measured with a high-sensitivity assay; HUNT Study, Nord-Trøndelag Health Study; LoD, limit of detection; eGFR, estimated glomerular filtration rate; ICD, International Statistical Classification of Diseases; IQR, interquartile range; HDL, high-density lipoprotein; BMI, body mass index; CRP, C-reactive protein; NRI, net reclassification index; IDI, integrated discrimination improvement; HR, hazard ratio; CI, confidence interval

**Abstract**

*Background:* Cardiac troponins are associated with cardiovascular risk in the general population, but whether temporal changes in cardiac troponin I provide independent prognostic information remains uncertain. Using a large community based cohort with follow-up to the present day, we aimed to investigate the associations between temporal changes in cardiac troponin and cardiovascular events.

*Methods:* We measured cardiac troponin I with a high-sensitivity assay (hs-cTnI) in 4805 subjects attending both the second (HUNT 2, 1995-97) and third wave (HUNT 3, 2006-2008) of the prospective observational Nord-Trøndelag Health (HUNT) Study. We constructed statistical models with both relative and absolute changes of hs-cTnI from HUNT 2 to HUNT 3. A composite endpoint of first admission for MI or HF, or cardiovascular death was generated.

*Results:* Participants with relative decrease in hs-cTnI were more frequently younger and female, and had lower blood pressure and body mass index. Participants with relative increase in hs-cTnI more frequently were older and male, with higher systolic blood pressure. The adjusted hazard ratio (HR) for relative increase in hs-cTnI was 1.68 (95% CI 1.16-2.42) and the adjusted HR for relative decrease was 1.19 (95% CI 0.84-1.68). Absolute increases in hs-cTnI exhibited similar prognostic properties as relative increases in hs-cTnI. The most recent measurement of hs-cTnI outperformed the change variables in discrimination and reclassification models.

*Conclusions:* Both relative and absolute increases in hs-cTnI are independently associated with cardiovascular risk. For refinement of risk prediction models, the most recent measurement of hs-cTnI should be preferred in clinical practice.

**Introduction**

Measurement of cardiac troponin with a high-sensitivity assay (hs-cTn) is essential in the diagnosis of acute coronary syndromes, as concentrations of hs-cTn are considered sensitive and specific indicators of myocardial injury *(*[*1*](#_ENREF_1)*)*. In recent years, hs-cTn measured in the general population has proven to be strongly associated with risk of fatal and non-fatal cardiovascular events *(*[*2*](#_ENREF_2)*)*. This risk may be ameliorated by interventions aimed at reducing cardiovascular risk, such as statin therapy, where concomitant reductions in risk and concentrations of hs-cTn have been demonstrated *(*[*3*](#_ENREF_3)*)*. Despite being interchangeable in the diagnosis of myocardial infarction (MI), in the chronic setting hs-cTnT and hs-cTnI are poorly correlated, and are differentially influenced by common cardiovascular risk factors *(*[*4*](#_ENREF_4)*)*. In addition, hs-cTnT exhibits a circadian variation, whereas hs-cTnI remains stable throughout the day and night *(*[*5*](#_ENREF_5)*)*. With regard to prognosis, there are differences between hs-cTnT and hs-cTnI, as hs-cTnT may be superior in predicting cardiovascular death and heart failure (HF) *(*[*6*](#_ENREF_6)*)*, while the associations with incident MI appear stronger for hs-cTnI *(*[*7*](#_ENREF_7)*)*.

Sampling of hs-cTn at multiple time points may have the potential to refine biomarker based risk estimation, and earlier studies have documented associations between temporal increases in hs-cTnT *(*[*8*](#_ENREF_8)*)* and hs-cTnI *(*[*9*](#_ENREF_9)*)* and increased risk of cardiovascular events. Whether these associations hold true also in a contemporary cohort of community dwellers with follow-up close to the present day is uncertain. Accordingly, using a large cohort of subjects recruited from the general population with measurements of hs-cTnI at two time points 10 years apart, we investigated the impact of temporal changes in hs‑cTnI on the risk of incident HF, MI, and cardiovascular death, using indices of relative and absolute changes in hs-cTnI. Additionally, we identified determinants of temporal changes in hs-cTnI in a general population.

**Methods**

*Study overview*  
The Nord-Trøndelag Health (HUNT) Study is the largest population-based cohort in Norway, with more than 120,000 participants from the Nord-Trøndelag county. Three waves have been conducted so far: HUNT 1 (1984-1986), HUNT 2 (1995-1997) and HUNT 3 (2006-2008) *(*[*10*](#_ENREF_10)*)*. The HUNT Study was approved by the Regional Committee for Medical Research Ethics and the Norwegian Data Inspectorate Board and all participants provided informed written consent.

*Participants*

In the current investigation, 5338 study subjects from four selected municipalities, with serum samples available for analyses from both HUNT 2 and HUNT 3, were included. Participants with known prior cardiovascular disease were excluded, leaving a total of 4805 participants for final analyses. Individual cardiovascular risk was estimated using the Systematic COronary Risk Evaluation *(*[*11*](#_ENREF_11)*)* and the Framingham risk score for Cardiovascular Disease *(*[*12*](#_ENREF_12)*)*.

*Blood sampling procedures and biochemical assays*Non-fasting venous blood samples were collected at HUNT 2 and 3, centrifuged at room temperature and frozen at -80°C. Serum samples from HUNT 2 underwent a thaw-freeze cycle in 2008 and were later stored at -20°C. For hs-cTnI analyses, serum samples were shipped on dry ice to Akershus University Hospital, Lørenskog, Norway. hs-cTnI was measured on the Architect i2000SR using an assay from Abbott Diagnostics, ARCHITECT STAT High Sensitive Troponin, the samples from HUNT 2 in 2014 and the samples from HUNT 3 in 2015. The same analyzer was used at both time points, but with different reagent lots. A detailed description of the assay methods has recently been published elsewhere *(*[*13*](#_ENREF_13)*)*. The limit of detection (LoD) for this assay is reported to be 1.2 ng/L *(*[*14*](#_ENREF_14)*)*. Concentrations below the LoD were assigned a value of 0.6 ng/L. Concentrations of hs-cTnI were detectable in 96.1% of subjects in HUNT 2 and in 72.2% of subjects in HUNT 3. Glomerular filtration rate was estimated (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration equation *(*[*15*](#_ENREF_15)*)*.

*Outcomes*Data on cardiovascular death (International Statistical Classification of Diseases [ICD], 9th Revision or 10th Revision codes 390–459 or I00–I99) were obtained from the Cause of Death Registry of Statistics Norway. Data on incident acute MI (ICD, 9th Revision or 10th Revision codes 410 or I21-I22) and admission for HF (codes 428 or I50) were obtained from hospital records; only hospitalizations where this diagnosis was listed as the primary diagnosis were included. All events were obtained through December 31, 2016.

*Statistical Methods*  
Baseline data are reported as absolute numbers (proportion) or median (interquartile range [IQR]) unless otherwise stated. Continuous variables were analyzed using the Mann-Whitney U test, and categorical variables with the Fisher exact test. Correlations were assessed by Spearman rank correlation. Change in hs-cTnI was modeled as relative change of < 50%, increase of ≥ 50%, or decrease of ≥ 50% from concentrations at HUNT 2 to HUNT 3, as previously suggested *(*[*8*](#_ENREF_8)*,* [*16*](#_ENREF_16)*)*. We also examined change in hs-cTnI as (1) incident elevation above concentrations as previously reported *(*[*17*](#_ENREF_17)*)* (progression from < 4.0ng/L [♀] and < 6.0ng/L [♂] at HUNT 2 to ≥ 4.0ng/L [♀] and ≥ 6.0ng/L [♂] at HUNT 3) and (2) incident elevation above the 99th centile (progression from < 16.0ng/L [♀] and < 34.0ng/L [♂] at HUNT 2 to ≥ 16.0ng/L [♀] and ≥ 34.0ng/L [♂] at HUNT 3). Separate models were also constructed for single-time point elevation in hs-cTnI at HUNT 3 using the same thresholds. Concentrations of hs-cTnI were transformed using the natural logarithm prior to use as a single covariate in all regression models.

A multinomial regression model was utilized to assess determinants of relative changes in hs-cTnI from HUNT 2 to HUNT 3. Adjustment was made for age and sex, as well as total cholesterol and high-density lipoprotein (HDL) cholesterol, history of hypertension and diabetes mellitus, current smoking, body mass index (BMI), eGFR, C-reactive protein (CRP), and hs-cTnI measured at HUNT 2.

For prognostic analyses, a composite endpoint of time to first event of admission for MI or HF, or cardiovascular death was generated, and participants were censored at the time of the composite endpoint. Remaining participants were censored at the time of death of other causes, or for survivors, on December 31, 2016. Cox proportional hazards regression models were generated to test the relationship between changes in hs-cTnI and time to events. Cumulative incidence plots were generated and the associations between groups according to changes in hs-cTnI and the composite endpoint were compared by the log-rank test. The survival models were adjusted for sex and age, as well total cholesterol and HDL cholesterol, history of hypertension and diabetes mellitus, current smoking, BMI, eGFR and CRP. Models with relative change in hs-cTnI were additionally adjusted for hs-cTnI measured at HUNT 3. Subjects with missing covariate data were excluded from the multivariable regression analyses. The incremental value of adding absolute and relative changes in hs-cTnI to the Systematic COronary Risk Evaluation risk score and the Framingham risk score for Cardiovascular Disease was examined by calculating the category-free net reclassification index (NRI) and integrated discrimination improvement (IDI) *(*[*18*](#_ENREF_18)*)* by the R package “PredictABEL” *(*[*19*](#_ENREF_19)*)*. Prognostic accuracy was assessed using *c*-statistics derived from the survival models and compared by the R package “survCOMP” *(*[*20*](#_ENREF_20)*,* [*21*](#_ENREF_21)*)*. Statistical significance was assumed at a *P* value <0.05. The following programs were used to conduct our statistical analysis: IBM SPSS Statistics for Windows, version 25 (IBM Corporation), STATA 15 (StataCorp LP), and R 3.4.3 (R Foundation for Statistical Computing). **Results**

*Determinants of changes in cardiac troponin I*

Baseline characteristics at HUNT 3 according to relative changes in hs-cTnI are outlined in **Table 1**. Study participants with relative decreases in hs-cTnI were more frequently younger and female, and had lower blood pressure and BMI. Participants with relative increases in hs-cTnI were more frequently older and male, with higher systolic blood pressure. Based on variables from HUNT 2, higher age, male sex, and lower total cholesterol and hs-cTnI were independent determinants of relative increase in hs-cTnI, whereas female sex, lower age, lower BMI, and higher total cholesterol and hs-cTnI were determinants of relative decrease in hs-cTnI (**Table 2**). Temporal changes in hs-cTnI were poorly correlated with temporal changes in BMI, blood pressure, blood cholesterol, renal function and CRP (online **Supplemental Table 1**). Considering the strong influence of sex and age on cardiac troponin, we assessed a possible non-linear association of age with temporal increase in hs-cTnI. For both sexes, risk of a relative increase in hs-cTnI was not present until ages were in the mid-forties, after which the risk increased steeply (**Figure 1**).

*Associations of cardiac troponin I with incident cardiovascular disease*

After a median follow-up time of 3503 (3248-3580) days, 249 events for the composite endpoint were registered. Concentrations of hs-cTnI at HUNT 3 were higher in participants experiencing the composite endpoint (3.9 [2.4-6.6] ng/L vs 1.7 [0.6-2.8] ng/L; *P* <0.001), and were associated with inferior prognosis in both crude (hazard ratio [HR] 2.06, 95% confidence interval [CI] 1.88-2.26) and adjusted analysis (HR 1.46, 95% CI 1.28-1.67).

*Associations of temporal changes in cardiac troponin I with incident cardiovascular disease*

The incidence rates per 1000 person years were higher in study participants exhibiting relative increases in hs-cTnI from HUNT 2 to HUNT 3 (**Table 3**). **Figure 2** demonstrates Kaplan-Meier survival curves according to changes in hs‑cTnI. Participants with relative increases in hs-cTnI had higher incidence rates compared to participants with no change (*P* by log-rank test <0.001), and participants with decreasing hs-cTnI had lower incidence rates compared to participants with no change (*P* = 0.037) and participants with increasing hs-cTnI (*P* <0.001). Study participants progressing above the two predefined thresholds of hs-cTnI also had higher incidence rates compared to participants with unchanged hs-cTnI (*P* <0.001 for both).

There was a significant association between both relative increase (HR 2.65, 95% CI 1.96-3.60) and decrease (HR 0.44, 95% CI 0.32-0.60) in hs-cTnI and cardiovascular death or admission for MI or HF in crude analyses. In adjusted analyses, the protective effect associated with decreasing hs-cTnI was attenuated (HR 1.19, 95% CI 0.84-1.68). The risk associated with increasing hs-cTnI, however, remained significant in the adjusted models (HR 1.68, 95% CI 1.16-2.42). Both incident elevation (HR 1.77, 95% CI 1.16-2.70) and single-time point elevation (HR 1.71, 95% CI 1.28-2.30) of hs-cTnI ≥ 4.0ng/L for women and ≥ 6.0ng/L for men, and incident elevation (HR 3.01, 95% CI 1.59-5.71) and single-time point elevation (HR 2.32, 95% CI 1.26-4.27) of hs‑cTnI ≥ 16.0ng/L for women and ≥ 34.0ng/L for men were associated with increased risk of events (**Table 3**).

Discrimination and reclassification models assessing the incremental prognostic value of hs‑cTnI are detailed in **Table 4**. The addition of hs-cTnI at HUNT 3 to the Systematic COronary Risk Evaluation risk score resulted in significant improvement in NRI and IDI. Adding relative change in hs-cTnI (≥ 50% increase in hs-cTnI vs rest) to this model did not improve model prediction. The addition of indices of absolute increases in hs-cTnI to the Systematic COronary Risk Evaluation risk score resulted in significant improvements in NRI (0.293 [0.168-0.418]), but no improvements in IDI (0.0067 [-0.0001-0.0135]) or *c*-statistics (0.834 [0.806-0.861] vs. 0.827 [0.799‑0.855]; *P*=0.05). The addition of single-time point elevation of hs-cTnI at HUNT 3 provided improvements in reclassification models superior to those of indices of absolute increases. The results from analyses using the Framingham risk score for Cardiovascular Disease as reference model were comparable to those using the Systematic COronary Risk Evaluation (online **Supplemental Table 2**).

*Associations of sex and temporal changes in cardiac troponin I*

For both men and women, there were strong associations between relative changes in hs‑cTnI from HUNT 2 to HUNT 3 and cardiovascular risk (**Table 3**). As for the entire cohort, the associations with decreasing hs-cTnI were attenuated for both sexes in adjusted models. Additionally, for women, the association with increasing hs-cTnI was attenuated in adjusted models. We did however not observe interactions between sex and relative changes in hs-cTnI (unadjusted *P*interaction=0.70, adjusted *P*interaction=0.53).

In the discrimination and reclassification models, the results were fairly similar as for the entire cohort (**Table 4**). The addition of hs-cTnI from HUNT 3 to the Systematic COronary Risk Evaluation risk score improved NRI and IDI for both sexes, but was stronger for women. The addition of relative change in hs-cTnI (≥ 50% increase in hs-cTnI vs rest) was not found to improve prediction models for either sex.

**Discussion**

In a large contemporary population-based cohort with measurements of biomarkers at two time points 10 years apart, both relative and absolute increases in hs-cTnI were associated with increased risk of cardiovascular death and admission for MI and HF. Absolute increases of hs-cTnI above predetermined thresholds strongly improved discrimination and reclassification models. The improvements were however inferior to the improvements provided by the most recent single-time point elevation in hs-cTnI. Sex and age, as well as blood cholesterol, were strong determinants of relative changes in hs-cTnI.

*Determinants of temporal changes in cardiac troponin*

Both age and sex are strongly associated with hs-cTnI *(*[*22*](#_ENREF_22)*)* and risk of incident cardiovascular disease *(*[*23*](#_ENREF_23)*,* [*24*](#_ENREF_24)*)*. In the current study, we additionally have demonstrated that male sex and higher age are associated with risk of significant *increases* in hs-cTnI over time. In contrast, younger females were at lower risk of significantly increasing concentrations of hs-cTnI, all independently of baseline concentrations of hs-cTnI. The risk of increasing concentrations of hs-cTnI was not evident until the fifth decade, consistent with midlife increases in cardiovascular risk. Changes in other cardiovascular risk factors such as BMI, blood pressure and blood cholesterol were poorly correlated with changes in hs-cTnI, and concomitant change in conventional risk factors cannot fully explain the relative changes in hs-cTnI observed in the current study.

Concentrations of total cholesterol were positively associated with risk of decreasing concentrations of hs-cTnI, and HDL cholesterol exhibited an inverse association. Total cholesterol is an independent risk factor for coronary heart disease, whereas HDL cholesterol is assumed to have cardioprotective properties *(*[*25*](#_ENREF_25)*)*. Statin therapy may be indicated in individuals with high total cholesterol, but the recommendation is weaker if concomitant concentrations of HDL cholesterol are high *(*[*26*](#_ENREF_26)*)*. Since HUNT 2, the use of statins has grown exponentially in Europe, and Norway is one of the countries with the highest prevalence of statin prescription in the world *(*[*27*](#_ENREF_27)*)*. In 2016, Ford et al. *(*[*3*](#_ENREF_3)*)* reported a 13% reduction in hs-cTnI measured with a high-sensitivity assay following treatment with statins compared with placebo. Even though we lack data on lipid modifying therapy in our cohort, it is not unreasonable to speculate that study participants with high concentrations of total cholesterol at baseline more frequently were prescribed a statin and consequently would experience reductions in hs-cTnI on follow-up due to this very phenomenon.

*Temporal changes in cardiac troponins and cardiovascular risk*

Concentrations of cardiac troponin are strongly associated with an adverse prognosis, both in subjects with established cardiovascular disease *(*[*6*](#_ENREF_6)*,* [*28*](#_ENREF_28)*)* and in previously healthy subjects recruited from the general population *(*[*2*](#_ENREF_2)*)*. Two previous studies investigating the temporal changes of cardiac troponin in presumably healthy individuals merit discussion in relation to the current study. Using data from the ARIC Study, McEvoy et al. *(*[*8*](#_ENREF_8)*)* examined the impact of six-year change in hs-cTnT on the risk of incident coronary heart disease, HF and cardiovascular death. Temporal changes in hs-cTnT were associated with clinical end points, and they found significant improvements in *c*-statistics and NRI for HF and cardiovascular death when implementing concentrations of hs-cTnT measured at two time points. More recently, Hughes et al. *(*[*9*](#_ENREF_9)*)* examined the association of change in hs-cTnI with incident cardiovascular disease in 3875 Danish community dwellers. They found significant associations between changes in hs-cTnI and risk of fatal and nonfatal cardiovascular disease, but change in hs-cTnI did not improve risk prediction models compared to the most recent single measurement of hs-cTnI. The results of the current study are principally in line with the aforementioned, but three important differences warrant mention.

First, evidence is currently amassing for both analytical and biological differences of hs-cTnT and hs-cTnI. Especially concerning for analyses of cardiac troponin concentrations close to the limit of detection is the circadian variation evident for hs-cTnT *(*[*5*](#_ENREF_5)*)*. Analyses focusing on relative changes in very low concentrations could easily be affected by such bias, in general making measurement of hs-cTnI preferable to hs-cTnT measurement in this setting.

Second, for both previous studies, follow-up of study participants started in the mid-nineties through 2009-2010. Our cohort was followed from 2006-2008 through 2016, and given the changes in population risk profile and spectrum of cardiovascular disease in the last twenty years *(*[*29*](#_ENREF_29)*)*, differences in study populations should be expected. The absolute number of events were lower in our study, more accurately reflecting contemporary incidence of cardiovascular morbidity and death in the general population.

Third, we firmly believe that a category-based approach is the most appropriate in the evaluation of change in cardiac troponin, despite assertions that more sensitive statistical models may be derived by using a continuous approach. For hs-cTnI and even more so for hs-cTnT *(*[*30*](#_ENREF_30)*)*, the biological and analytical variation is high and the use of a continuous approach leaves the question of whether actual change in biomarker concentrations has occurred.

*Discrimination and reclassification*

The incremental value of relative increases in hs-cTnI to established risk models and single-time point measurements of hs-cTnI was limited. Absolute increases in hs-cTnI surpassing thresholds within the reference interval (≥ 4.0ng/L for women and ≥ 6.0ng/L for men), on the other hand, provided strong improvements in NRI, as well as weaker improvements in IDI. The improvements provided by single-time point elevations in hs-cTnI were superior to those provided by delta values obtained from serial measurements. Using the most recent measurement of hs-cTnI in such a dichotomized manner, accordingly, may be preferred when predicting risk of incident cardiovascular disease. Nevertheless, considering the pronounced cardiovascular risk associated with cardiac troponin, we believe that an increase in cardiac troponin on serial sampling should merit increased vigilance with regard to investigation and possible preventive measures. Our data do not enable us to estimate the optimal interval for serial testing.

*The impact of sex*

Sex is one of the strongest determinants of cardiovascular risk and men generally develop cardiovascular disease a decade before their female counterparts. After menopause and in the later decades, the cardiovascular risk differences attributable to sex seem to diminish *(*[*31*](#_ENREF_31)*,* [*32*](#_ENREF_32)*)*. Cardiac troponins are also affected by sex, and women exhibit lower concentrations than men for both hs-cTnT and hs-cTnI. The relative risk associated with cardiac troponins, however, appears stronger in women, especially for prediction of incident MI *(*[*33*](#_ENREF_33)*)* and cardiovascular death *(*[*13*](#_ENREF_13)*)* in presumably healthy subjects recruited from the general population.

Both absolute and relative increases in hs-cTnI were associated with unfavorable outcomes in the current study. For absolute changes, we used sex specific cut-offs as previously established. In the models constructed on relative changes in hs-cTnI, the association with risk was attenuated for women. These models were also adjusted for baseline hs-cTnI. As the prognostic impact of single-time point measurements of hs‑cTnI is significantly stronger in women *(*[*13*](#_ENREF_13)*,* [*33*](#_ENREF_33)*)*, it is not entirely surprising that this adjustment would attenuate the association with relative changes in hs-cTnI. Considering the weaker association with single-time point measurements of hs-cTnI in men, it is possible that men may benefit to a greater extent from serial measurements with calculation of delta values of cardiac troponins compared to women. However, given that the prognostic value of the most recent measurement tended to be stronger in women, the recommended frequency of measurement should probably be the same for both sexes.

*Strengths and limitations*

The current study has its strengths and limitations. The analyses are based on a substantial sample from a contemporary prospective cohort with a relatively large number of clinical end points assessed up to the current date. Concentrations of hs‑cTnI were additionally measured with one of the most sensitive assays currently available. Observational bias cannot be excluded, as clinical end points were based on diagnosis codes from hospital records and not from a study end point adjudication committee. The lack of data on medication is an obvious limitation, especially considering the impact of lipid lowering agents on concentrations of cardiac troponins. Cardiac imaging data examining longitudinal changes in cardiac structure and function could have provided additional mechanistic insights to temporal changes in hs-cTnI, as left ventricular mass strongly influences concentrations of cardiac troponin *(*[*34*](#_ENREF_34)*)*. Although the assay used was one of the most sensitive on the market, the analytical precision was not as good in the low as it was in the medium to high portions of the reference interval. This is also reflected in the different proportions of subjects with detectable concentrations of hs-cTnI in HUNT 2 and HUNT 3. Variability between reagent lots for hs-cTnI is most likely the cause of this discrepancy *(*[*35*](#_ENREF_35)*)*. Detection of an increase in concentrations is accordingly likely to be more robust and less influenced by noise, than detection of a reduction. This may have contributed to the attenuation of the association between reductions in hs-cTnI concentrations and outcome. Finally, given the observational nature of the study, we cannot rule out residual confounding influencing our results.

**Conclusions**In a large contemporary cohort recruited from the general population, temporal increases in hs-cTnI were associated with increased risk of cardiovascular death and admission for MI and HF. For refinement of clinical risk prediction models, the most recent measurement of hs‑cTnI was found to outperform serial measurements. Therefore, single-time point measurement should be preferred in clinical practice.

**Acknowledgments**

The Nord-Trøndelag Health Study (The HUNT Study) is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology), Nord-Trøndelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health.**References**

1. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019;40:237-69.

2. Willeit P, Welsh P, Evans JDW, Tschiderer L, Boachie C, Jukema JW, et al. High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular outcomes in 154,052 participants. J Am Coll Cardiol 2017;70:558-68.

3. Ford I, Shah AS, Zhang R, McAllister DA, Strachan FE, Caslake M, et al. High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. J Am Coll Cardiol 2016;68:2719-28.

4. Welsh P, Preiss D, Shah ASV, McAllister D, Briggs A, Boachie C, et al. Comparison between high-sensitivity cardiac troponin T and cardiac troponin I in a large general population cohort. Clin Chem 2018;64:1607-16.

5. Klinkenberg LJ, Wildi K, van der Linden N, Kouw IW, Niens M, Twerenbold R, et al. Diurnal rhythm of cardiac troponin: Consequences for the diagnosis of acute myocardial infarction. Clin Chem 2016;62:1602-11.

6. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009;361:2538-47.

7. Omland T, Pfeffer MA, Solomon SD, de Lemos JA, Rosjo H, Saltyte Benth J, et al. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol 2013;61:1240-9.

8. McEvoy JW, Chen Y, Ndumele CE, Solomon SD, Nambi V, Ballantyne CM, et al. Six-year change in high-sensitivity cardiac troponin T and risk of subsequent coronary heart disease, heart failure, and death. JAMA Cardiol 2016;1:519-28.

9. Hughes MF, Ojeda F, Saarela O, Jorgensen T, Zeller T, Palosaari T, et al. Association of repeatedly measured high-sensitivity-assayed troponin I with cardiovascular disease events in a general population from the MORGAM/BiomarCaRE Study. Clin Chem 2017;63:334-42.

10. Krokstad S, Langhammer A, Hveem K, Holmen TL, Midthjell K, Stene TR, et al. Cohort profile: The HUNT study, Norway. Int J Epidemiol 2013;42:968-77.

11. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in europe: The SCORE project. Eur Heart J 2003;24:987-1003.

12. D'Agostino Sr. RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 2008;117:743-53.

13. Omland T, de Lemos JA, Holmen OL, Dalen H, Benth JS, Nygard S, et al. Impact of sex on the prognostic value of high-sensitivity cardiac troponin I in the general population: The HUNT study. Clin Chem 2015;61:646-56.

14. Apple FS, Collinson PO, IFCC Task Force on Clinical Applications of Cardiac Biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012;58:54-61.

15. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.

16. deFilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, Seliger SL. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010;304:2494-502.

17. Sigurdardottir FD, Lyngbakken MN, Holmen OL, Dalen H, Hveem K, Rosjo H, Omland T. Relative prognostic value of cardiac troponin I and C-reactive protein in the general population (from the Nord-Trondelag Health [HUNT] Study). Am J Cardiol 2018;121:949-55.

18. Pencina MJ, D'Agostino RB, Sr., Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.

19. Kundu S, Aulchenko YS, van Duijn CM, Janssens AC. PredictABEL: An R package for the assessment of risk prediction models. Eur J Epidemiol 2011;26:261-4.

20. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: Model specific population value and confidence interval estimation. Stat Med 2004;23:2109-23.

21. Schroder MS, Culhane AC, Quackenbush J, Haibe-Kains B. Survcomp: An R/Bioconductor package for performance assessment and comparison of survival models. Bioinformatics 2011;27:3206-8.

22. Gore MO, Seliger SL, Defilippi CR, Nambi V, Christenson RH, Hashim IA, et al. Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. J Am Coll Cardiol 2014;63:1441-8.

23. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999;353:89-92.

24. Savji N, Rockman CB, Skolnick AH, Guo Y, Adelman MA, Riles T, Berger JS. Association between advanced age and vascular disease in different arterial territories: A population database of over 3.6 million subjects. J Am Coll Cardiol 2013;61:1736-43.

25. Peters SA, Singhateh Y, Mackay D, Huxley RR, Woodward M. Total cholesterol as a risk factor for coronary heart disease and stroke in women compared with men: A systematic review and meta-analysis. Atherosclerosis 2016;248:123-31.

26. Ray KK, Kastelein JJ, Boekholdt SM, Nicholls SJ, Khaw KT, Ballantyne CM, et al. The ACC/AHA 2013 Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: The good the bad and the uncertain: A comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014;35:960-8.

27. Walley T, Folino-Gallo P, Schwabe U, van Ganse E, EuroMedStat group. Variations and increase in use of statins across europe: Data from administrative databases. BMJ 2004;328:385-6.

28. Samman Tahhan A, Sandesara P, Hayek SS, Hammadah M, Alkhoder A, Kelli HM, et al. High-sensitivity troponin I levels and coronary artery disease severity, progression, and long-term outcomes. J Am Heart Assoc 2018;7:e007914.

29. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol 2017;70:1-25.

30. Vasile VC, Saenger AK, Kroning JM, Jaffe AS. Biological and analytical variability of a novel high-sensitivity cardiac troponin T assay. Clin Chem 2010;56:1086-90.

31. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population. Am Heart J 1986;111:383-90.

32. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics--2015 update: A report from the American Heart Association. Circulation 2015;131:e29-322.

33. Lyngbakken MN, Rosjo H, Holmen OL, Nygard S, Dalen H, Hveem K, Omland T. Gender, high-sensitivity troponin I, and the risk of cardiovascular events (from the Nord-Trondelag Health Study). Am J Cardiol 2016;118:816-21.

34. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010;304:2503-12.

35. Kavsak PA, Worster A, Oliver R, Clark L, Parry D, Randell E, et al. Variability between reagent lots for high-sensitivity cardiac troponin I may affect performance of early rule out strategies. Can J Cardiol 2018;34:209.e5-e6.

**Text tables**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table 1.** Baseline characteristics at HUNT 3 according to relative change in cardiac troponin I from HUNT 2 to HUNT 3 | | | | | | |
|  | Change in cardiac troponin I | | | | | |
|  | ≥50% decrease | | <50% change | | ≥50% increase | |
|  | n | Value | n | Value | n | Value |
| Female sex, n (%) | 1991 | 1241 (62.3)c | 2396 | 1293 (54.0) | 418 | 189 (45.2)b |
| Age, years | 1991 | 51.6 (43.9-60.4)c | 2396 | 59.5 (49.9-68.5) | 418 | 61.5 (50.7-74.2)b |
| Current smoker, n (%) | 1955 | 370 (18.9)b | 2340 | 368 (15.7) | 404 | 49 (12.1)a |
| Alcohol consumption, units/2 weeks | 1206 | 3 (0-6) | 1377 | 3 (0-7) | 248 | 3 (0-8) |
| Body weight, kg | 1989 | 77.4 (67.0-88.1)c | 2387 | 78.8 (69.5-89.0) | 411 | 80.1 (69.2-87.9) |
| BMI, kg/m2 | 1989 | 26.4 (23.9-29.4)c | 2386 | 27.0 (24.6-29.8) | 411 | 26.6 (24.6-29.4) |
| Systolic blood pressure, mmHg | 1990 | 126 (117-137)c | 2392 | 136 (124-149) | 417 | 139 (124-155)a |
| Diastolic blood pressure, mmHg | 1990 | 73 (66-80)c | 2392 | 76 (69-83) | 417 | 75 (68-84) |
| Hypertension, n (%) | 1990 | 622 (31.3)c | 2392 | 1251 (52.3) | 417 | 234 (56.1) |
| Diabetes mellitus, n (%) | 1991 | 66 (3.3) | 2396 | 100 (4.2) | 418 | 27 (6.5)a |
| Glucose nonfasting, mg/dLd | 1973 | 97 (88-106)c | 2379 | 97 (90-110) | 413 | 99 (90-112) |
| Triglycerides nonfasting, mg/dLd | 1991 | 124 (89-186)b | 2395 | 133 (89-186) | 418 | 124 (89-177)b |
| Total cholesterol, mg/dLd | 1973 | 220 (193-244)c | 2379 | 224 (197-255) | 412 | 217 (190-244)c |
| HDL cholesterol, mg/dLd | 1973 | 50 (43-62)b | 2379 | 50 (43-62) | 412 | 54 (43-62) |
| eGFR, ml/min/1.73m2 | 1991 | 83.8 (74.1-94.7)c | 2395 | 77.7 (66.8-89.5) | 418 | 75.7 (64.7-88.1)a |
| CRP, mg/L | 1991 | 1.1 (0.5-2.5)c | 2395 | 1.4 (0.7-2.7) | 418 | 1.6 (0.8-3.0)a |
| Cardiac troponin I (HUNT 2), ng/L | 1991 | 2.9 (2.1-4.0)b | 2396 | 3.0 (2.2-4.2) | 418 | 3.0 (1.8-4.6) |
| Cardiac troponin I (HUNT 3), ng/L | 1991 | 0.6 (0.6-1.5)c | 2396 | 2.3 (1.7-3.5) | 418 | 6.5 (3.7-11.4)c |
| a*P*<0.05, b*P*<0.01, c*P*<0.001 versus <50% change, dTo convert glucose concentrations from mg/dL to mmol/L, multiply by 0.05556. To convert triglyceride concentrations from mg/dL to mmol/L, multiply by 0.01129. To convert cholesterol concentrations from mg/dL to mmol/L, multiply by 0.02586. | | | | | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 2.** Determinants of relative change in cardiac troponin I from HUNT 2 to HUNT 3 | | | | |
|  | Odds ratio (95% CI) | | | |
|  | Univariable | | Multivariable | |
|  | ≥ 50% decrease | ≥ 50% increase | ≥ 50% decrease | ≥ 50% increase |
| Female sex | 1.41 (1.25-1.59) | 0.70 (0.57-0.87) | 2.12 (1.82-2.48) | 0.56 (0.44-0.73) |
| Age | 0.96 (0.95-0.96) | 1.01 (1.01-1.02) | 0.95 (0.94-0.96) | 1.03 (1.02-1.04) |
| Current smoking | 1.24 (1.08-1.42) | 0.88 (0.69-1.14) | 1.07 (0.93-1.25) | 0.92 (0.71-1.20) |
| BMI | 0.96 (0.94-0.97) | 0.98 (0.96-1.01) | 0.97 (0.95-0.99) | 0.99 (0.96-1.02) |
| Hypertension | 0.43 (0.38-0.49) | 1.18 (0.96-1.46) | 0.61 (0.52-0.71) | 1.15 (0.91-1.46) |
| Diabetes mellitus | 0.53 (0.29-0.96) | 2.27 (1.21-4.25) | 0.85 (0.45-1.61) | 1.68 (0.86-3.26) |
| Total cholesterol | 0.91 (0.86-0.95) | 0.88 (0.81-0.97) | 1.14 (1.07-1.22) | 0.83 (0.75-0.93) |
| HDL cholesterol | 0.81 (0.69-0.94) | 1.05 (0.81-1.36) | 0.66 (0.55-0.80) | 1.19 (0.88-1.59) |
| eGFR | 1.02 (1.02-1.03) | 1.00 (0.99-1.01) | 1.01 (1.00-1.01) | 1.00 (0.99-1.01) |
| CRP | 1.00 (0.98-1.01) | 1.01 (0.99-1.03) | 0.99 (0.98-1.01) | 1.01 (0.99-1.03) |
| Cardiac troponin I | 1.05 (0.95-1.15) | 0.85 (0.72-1.00) | 1.84 (1.62-2.08) | 0.63 (0.51-0.78) |
| Odds ratio compared to participants with < 50% change. All independent determinants assessed at HUNT 2. | | | | |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 3.** Associations of changes in cardiac troponin I from HUNT 2 to HUNT 3 with incident myocardial infarction, heart failure, or cardiovascular death. | | | | | | | | | |
|  |  | ≥50% decrease (1241 women, 750 men) | | | <50% change (1293 women, 1103 men) | | | ≥50% increase (189 women, 229 men) | |
|  | Women | 23 | | | 58 | | | 23 | |
| Number of events | Men | 29 | | | 80 | | | 36 | |
|  | Both sexes | 52 | | | 138 | | | 59 | |
|  | Women | 2.1b | | | 5.0 | | | 13.7b | |
| Incidence rate (per 1000 patient years) | Men | 4.2a | | | 8.1 | | | 19.1b | |
|  | Both sexes | 2.8b | | | 6.4 | | | 16.9b | |
|  | Women  (n = 2723) | 0.40 (0.25-0.65) | | |  | | | 2.89 (1.78-4.68) | |
| HR (unadjusted) | Men  (n = 2082) | 0.52 (0.34-0.79) | | | Reference | | | 2.37 (1.60-3.52) | |
|  | Both sexes (n = 4805) | 0.44 (0.32-0.60) | | |  | | | 2.65 (1.96-3.60) | |
|  | Women  (n = 2614) | 1.24 (0.72-2.14) | | |  | | | 1.65 (0.90-3.01) | |
| HR (adjusted) | Men  (n = 2022) | 1.11 (0.70-1.75) | | | Reference | | | 1.65 (1.04-2.62) | |
|  | Both sexes  (n = 4636) | 1.19 (0.84-1.68) | | |  | | | 1.68 (1.16-2.42) | |
|  |  |  | |  | | |  | | |
|  |  | hs-cTnI < 4.0ng/L (♀), < 6.0ng/L (♂) (HUNT 2); hs-cTnI ≥ 4.0ng/L (♀), ≥ 6.0ng/L (♂) (HUNT 3) | | | | hs-cTnI < 16.0ng/L (♀), < 34.0ng/L (♂) (HUNT 2); hs-cTnI ≥ 16.0ng/L (♀), ≥ 34.0ng/L (♂) (HUNT 3) | | | |
|  |  | No (n = 3747) | Yes (n = 235) | | | No (n = 4721) | | | Yes (n = 49) |
| Number of events |  | 128 | 33 | | | 235 | | | 10 |
| Incidence rate (per 1000 patient years) |  | 3.7 | 16.8b | | | 5.5 | | | 25.1b |
| HR (unadjusted) |  | Reference | 4.61 (3.14-6.76) | | | Reference | | | 4.65 (2.47-8.75) |
| HR (adjusted) |  | Reference | 1.77 (1.16-2.70) | | | Reference | | | 3.01 (1.59-5.71) |
|  |  |  |  | | |  | | |  |
|  |  | hs-cTnI ≥ 4.0ng/L (♀), ≥ 6.0ng/L (♂) (HUNT 3) | | | | hs-cTnI ≥ 16.0ng/L (♀), ≥ 34.0ng/L (♂) (HUNT 3) | | | |
|  |  | No (n = 4221) | Yes (n = 584) | | | No (n = 4741) | | | Yes (n = 64) |
| Number of events |  | 162 | 87 | | | 237 | | | 12 |
| Incidence rate (per 1000 patient years) |  | 2.3 | 33.7b | | | 5.5 | | | 23.2b |
| HR (unadjusted) |  | Reference | 4.38 (3.38-5.69) | | | Reference | | | 4.26 (2.39-7.62) |
| HR (adjusted) |  | Reference | 1.71 (1.28-2.30) | | | Reference | | | 2.32 (1.26-4.27) |
| a*P* < 0.01, b*P* < 0.001 compared to reference (<50% change or no elevation in concentrations of hs-cTnI). Adjusted model includes age, sex, total cholesterol and HDL cholesterol, history of hypertension and diabetes mellitus, current smoking, BMI, eGFR, CRP. Models with relative changes in hs-cTnI additionally adjusted for hs-cTnI measured at HUNT 3. | | | | | | | | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 4.** Incremental prognostic value of cardiac troponin I to established risk prediction algorithms | | | | |
|  |  | Net reclassification index | Integrated discrimination improvement | *c* statistics |
|  | SCORE (reference) |  |  | 0.854 (0.822-0.887) |
| Women | SCORE + hs-cTnI | 0.674 (0.482-0.866)c | 0.0263 (0.0092-0.0435)b | 0.835 (0.795-0.874) |
|  | SCORE + hs-cTnI+ Δ hs-cTnI | -0.203 (-0.397- -0.009)a | 0.0007 (-0.0005-0.0018) | 0.834 (0.794-0.874) |
|  | SCORE (reference) |  |  | 0.789 (0.755-0.823) |
| Men | SCORE + hs-cTnI | 0.475 (0.307-0.643)c | 0.0192 (0.0078-0.0306)c | 0.763 (0.722-0.803)a |
|  | SCORE + hs-cTnI+ Δ hs-cTnI | -0.092 (-0.255-0.070) | 0.0008 (-0.0007-0.0022) | 0.762 (0.722-0.802)a |
|  | SCORE (reference) |  |  | 0.826 (0.803-0.849) |
| Both sexes | SCORE + hs-cTnI | 0.624 (0.498-0.750)c | 0.0250 (0.0145-0.0356)c | 0.804 (0.777-0.832)a |
|  | SCORE + hs-cTnI+ Δ hs-cTnI | -0.159 (-0.282- -0.035)a | 0.0008 (-0.0004-0.0017) | 0.804 (0.776-0.803)a |
| Both sexes | SCORE (reference) |  |  | 0.834 (0.806-0.861) |
| SCORE + incident elevation hs-cTnI ≥ 4.0ng/L (♀) and ≥ 6.0ng/L (♂) | 0.293 (0.168-0.418)c | 0.0067 (-0.0001-0.0135) | 0.827 (0.799-0.855) |
| SCORE (reference) |  |  | 0.830 (0.808-0.852) |
| SCORE + incident elevation hs-cTnI ≥ 16.0ng/L (♀) and ≥ 34.0ng/L (♂) | 0.068 (0.016-0.199)a | 0.0053 (-0.0002-0.0107) | 0.827 (0.805-0.849)a |
| SCORE (reference) |  |  | 0.826 (0.803-0.849) |
| SCORE +  single-time point elevation hs-cTnI  ≥ 4.0ng/L (♀) and ≥ 6.0ng/L (♂) | 0.466 (0.345-0.587)c | 0.0093 (0.0029-0.0158)b | 0.819 (0.797-0.841) |
| SCORE (reference) |  |  | 0.826 (0.803-0.849) |
| SCORE +  single-time point elevation hs-cTnI  ≥ 16.0ng/L (♀) and ≥ 34.0ng/L (♂) | 0.077 (0.022-0.132)b | 0.0044 (-0.0004-0.0092) | 0.826 (0.804-0.848) |
| Δ hs-cTnI, ≥50% increase in hs-cTnI vs rest. a*P*<0.05, b*P*<0.01, c*P*<0.001 compared to reference model. | | | | |

**Figure legends**

**Figure 1.** Association of baseline age at HUNT 2 with risk of increasing concentrations hs-cTnI. Adjusted restricted cubic spline models centered at the median, 45.9 years (♀) and 45.2 years (♂). OR, odds ratio for trend above and below median.

**Figure 2.** Kaplan-Meier plots for the composite endpoint of cardiovascular death or admission for MI or HF. Subjects stratified according to **(A)** relative change in hs-cTnI from HUNT 2 to HUNT 3, **(B)** incident elevation ≥ 4.0 ng/L (♀), ≥ 6.0ng/L (♂) from HUNT 2 to HUNT 3 and **(C)** incident elevation ≥ 16.0ng/L (♀), ≥ 34.0ng/L (♂) from HUNT 2 to HUNT 3.